REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have earned a consensus rating of “Moderate Buy” from the six research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $31.88.

A number of equities analysts have recently commented on the stock. The Goldman Sachs Group lowered shares of REGENXBIO from a “buy” rating to a “neutral” rating and dropped their price target for the company from $38.00 to $14.00 in a research report on Tuesday, February 11th. Raymond James assumed coverage on shares of REGENXBIO in a report on Friday, February 7th. They issued an “outperform” rating and a $27.00 target price on the stock. Chardan Capital restated a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a report on Thursday, March 20th. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, March 7th. Finally, Leerink Partners set a $24.00 target price on REGENXBIO in a research note on Tuesday, March 18th.

Institutional Trading of REGENXBIO

Institutional investors have recently modified their holdings of the company. FMR LLC boosted its stake in REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,656 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of REGENXBIO by 602.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company’s stock worth $214,000 after acquiring an additional 17,533 shares during the period. Stifel Financial Corp lifted its holdings in shares of REGENXBIO by 13.3% during the 3rd quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company’s stock worth $1,566,000 after acquiring an additional 17,563 shares during the period. Barclays PLC boosted its position in shares of REGENXBIO by 141.3% during the 3rd quarter. Barclays PLC now owns 116,024 shares of the biotechnology company’s stock valued at $1,217,000 after acquiring an additional 67,948 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in REGENXBIO by 4.2% in the third quarter. Geode Capital Management LLC now owns 1,088,651 shares of the biotechnology company’s stock valued at $11,422,000 after acquiring an additional 44,037 shares during the period. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Stock Up 3.5 %

NASDAQ RGNX opened at $6.55 on Wednesday. The company has a 50 day moving average price of $6.92 and a two-hundred day moving average price of $8.23. REGENXBIO has a 12-month low of $5.04 and a 12-month high of $18.24. The stock has a market capitalization of $328.27 million, a PE ratio of -1.30 and a beta of 1.26.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The business had revenue of $21.21 million during the quarter, compared to analyst estimates of $23.70 million. As a group, equities analysts anticipate that REGENXBIO will post -4.84 EPS for the current year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.